You are here: Industry Insights > Market News > Lupin gets warning letter from US FDA for Somerset facility

Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!

Note: You can unsubscribe from the alerts at any time.

Advertising

Hot Products

Propantheline Bromide

carbomer 974P

Coenzyme Q10

Refined Fish Oil

Black Currant Extract

Hydrocortisone

Lupin gets warning letter from US FDA for Somerset facility

expresspharmaJune 16, 2021

Tag: lupin , FDA , Lupin Somerset

Favorites

Lupin has received a warning letter from the US FDA for the company’s Somerset, New Jersey facility. The US FDA had inspected the Lupin Somerset site from September 10, 2020, to November 5, 2020.

A statement from Lupin informed, “The company does not believe that the warning letter will have an impact on disruption of supplies or the existing revenues from operations of this facility. We are committed to addressing the concerns raised by the US FDA and will work with the FDA and the New Jersey District to resolve these issues at the earliest.”

Previous:Natco gets US FDA approval for Carfilzomib vials

Next:Training healthcare workers and pharmacists against fraudulent medicines is a must: ASPA

InnoCare Announces First Patient Dosed in Clinical Trial of BCL2 Inhibitor ICP-248 in Combination with Orelabrutinib as First-Line Therapy for Chronic Lymphocytic Leukemia /Small Lymphocytic Lymphoma

PharmaSourcesMay 21, 2024

The first patient has been dosed in a clinical trial of the Company's BCL2 inhibitor, ICP-248, in combination with orelabrutinib as a first-line therapy for chronic lymphocytic leukemia /small lymphocytic lymphoma (CLL/SLL) in China.

Selection of Commercial Models for Innovative Drugs

PharmaSourcesMay 21, 2024

Sartorius to Advance Drug Discovery and Manufacturing with AI in Collaboration with NVIDIA

Biotech NewswireMay 17, 2024

Lupin gets warning letter from US FDA for Somerset facility | Pharmasources.com

InnoCare Announces the Completion of Patient Enrollment in the Phase II Clinical Trial of ICP-488 for the Treatment of Psoriasis

PharmaSourcesMay 16, 2024

InnoCare announced the completion of patient enrollment for the phase II clinical trial of ICP-488, a TYK2 (tyrosine kinase 2) JH2 allosteric inhibitor, for the treatment of psoriasis.

Lupin gets warning letter from US FDA for Somerset facility

Related News

InnoCare Announces First Patient Dosed in Clinical Trial of BCL2 Inhibitor ICP-248 in Combination with Orelabrutinib as First-Line Therapy for Chronic Lymphocytic Leukemia /Small Lymphocytic Lymphoma

Selection of Commercial Models for Innovative Drugs

Sartorius to Advance Drug Discovery and Manufacturing with AI in Collaboration with NVIDIA

InnoCare Announces the Completion of Patient Enrollment in the Phase II Clinical Trial of ICP-488 for the Treatment of Psoriasis

You may like